Stocks & Investing
Stocks and Investing
Stocks and Investing
Fri, August 11, 2023
[ Fri, Aug 11th 2023
] - WOPRAI
[ Fri, Aug 11th 2023
] - WOPRAI
[ Fri, Aug 11th 2023
] - WOPRAI
[ Fri, Aug 11th 2023
] - WOPRAI
[ Fri, Aug 11th 2023
] - WOPRAI
[ Fri, Aug 11th 2023
] - WOPRAI
[ Fri, Aug 11th 2023
] - WOPRAI
[ Fri, Aug 11th 2023
] - WOPRAI
[ Fri, Aug 11th 2023
] - WOPRAI
[ Fri, Aug 11th 2023
] - WOPRAI
[ Fri, Aug 11th 2023
] - WOPRAI
[ Fri, Aug 11th 2023
] - WOPRAI
[ Fri, Aug 11th 2023
] - WOPRAI
[ Fri, Aug 11th 2023
] - WOPRAI
[ Fri, Aug 11th 2023
] - WOPRAI
[ Fri, Aug 11th 2023
] - WOPRAI
[ Fri, Aug 11th 2023
] - WOPRAI
[ Fri, Aug 11th 2023
] - WOPRAI
[ Fri, Aug 11th 2023
] - WOPRAI
[ Fri, Aug 11th 2023
] - WOPRAI
[ Fri, Aug 11th 2023
] - WOPRAI
[ Fri, Aug 11th 2023
] - WOPRAI
[ Fri, Aug 11th 2023
] - WOPRAI
[ Fri, Aug 11th 2023
] - WOPRAI
[ Fri, Aug 11th 2023
] - WOPRAI
[ Fri, Aug 11th 2023
] - WOPRAI
[ Fri, Aug 11th 2023
] - WOPRAI
[ Fri, Aug 11th 2023
] - WOPRAI
[ Fri, Aug 11th 2023
] - WOPRAI
[ Fri, Aug 11th 2023
] - WOPRAI
Ed Arce Reiterated (AKBA) at Hold and Held Target at $2 on, Aug 11th, 2023
Ed Arce of HC Wainwright & Co., Reiterated "Akebia Therapeutics, Inc." (AKBA) at Hold and Held Target at $2 on, Aug 11th, 2023.
Ed has made no other calls on AKBA in the last 4 months.
There is 1 other peer that has a rating on AKBA. Out of the 1 peers that are also analyzing AKBA, 0 agree with Ed's Rating of Hold.
This is the rating of the analyst that currently disagrees with Ed
- Christopher Raymond of "Piper Sandler" Upgraded from Hold to Buy and Increased Target to $4 on, Wednesday, May 31st, 2023
